BETHESDA, Md.--(BUSINESS WIRE)--REGENERX BIOPHARMACEUTICALS, INC. (NYSE Alternext US:RGN) announced today that it has completed enrollment and dosing of 40 healthy volunteers for its Phase IB double-blind, placebo-controlled clinical trial testing RGN-352, an injectable formulation of Tß4 for potential use in treating acute myocardial infarction patients (AMI or heart attack). The trial included four groups of ten subjects each to assess the safety and tolerability of escalating doses of RGN-352 injected daily into the blood stream over a 14-day period. To date, RGN-352 appears safe and well-tolerated. There have been no serious drug-related adverse events. A final analysis and report will be submitted to the U.S. Food and Drug Administration in approximately 180 days.
